Ev
Evolva
Reinach CHFounded 200450 employees
Private CapbiotechAcquiredOncology
Platform: Synth Bio Ingredients
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| EVO-5421 | EVO-5421 | Preclinical | 1 | GLP-1R | Asthma | ||
| Tixanesiran | EVO-4987 | Phase 2 | 2 | PRMT5 | Bladder CaRSV | ||
| Gelisacituzumab | EVO-5400 | Phase 1 | 1 | AuroraA | Heart Failure |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (2)